Biomarkers.

Background: Plasma biomarkers may be a non-invasive and cost-effective tool for diagnosing Alzheimer's Disease. Promising markers include amyloid-β-42/40 ratio (Aβ-42/40), glial fibrillary acidic protein (GFAP), and neurofilament-light (NfL). Not much is known about what genetic and environmental factors influence and potentially confound these biomarker levels.

Biomarkers.

Background: Blood-based biomarkers (BBM) for Alzheimer's disease (AD) may be able to identify individuals eligible for emerging anti-amyloid treatments (DMT). We aimed to evaluate how to use BBM as (pre-) selection tools for DMTs by simulating different triaging scenarios in a memory clinic setting.

Methods: We included 1199 participants from the Amsterdam Dementia Cohort with measured BBM (plasma pTau181, GFAP and NfL) and used a predefined Youden-index based cut point for amyloid positivity (method: https://doi.

Biomarkers.

Background: Blood-based biomarkers (BBM) are emerging as minimally invasive, scalable and relatively low-cost options for discriminating different neurodegenerative diseases. Before implementation in clinical practice can take place, it is important to determine their real-world clinical validity in patients presenting at a memory clinic. Therefore, we prospectively evaluated changes in diagnosis and diagnostic confidence resulting from the use of a BBM panel tailored to common differential diagnostic considerations (Verberk et al.

Identifying Needs and Support Services for Family Caregivers of Older Community-Based Family Members: Mixed-Method Research Findings.

A recent Canadian study conducted in one province identified family caregiver support needs and essential support services when caring for older community-based family members requiring assistance with activities of daily living. Weekly interviews of 150 volunteer caregivers over 6 months identified 11 support needs and 5 essential support services. Scoping literature reviews of the 11 needs found they had all been identified before.

Biomarkers.

Background: Plasma levels of amyloid-β, and glial fibrillary acidic protein (GFAP) have demonstrated predictive potential for amyloid pathology in the early stages of Alzheimer's disease (AD) development. Utilizing baseline and up to 6-year follow-up plasma, positron emission tomography (PET) and cognitive data from cognitively unimpaired individuals, we here aim to test whether early changes in plasma biomarker levels associate with change in amyloid status and cognitive decline.

Methods: From the EMIF-AD PreclinAD study we selected individuals with normal cognition and longitudinal plasma, PET and cognitive data available (n=200, table 1).